Entasis Announces $31.9 Million Extension of Series B Financing to Advance Anti-infective Therapeutic Portfolio
Series B-1 Funding will Support the Company’s Programs to Treat Multidrug-Resistant Gram-negative InfectionsWALTHAM, Mass. — August, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products,…